Catalent reports that Sharon Johnson, Senior Vice President, Global Quality & Regulatory Affairs, is to head up Catalent’s newly formed Quality, Product Development & Regulatory Affairs organization. One of the key functions of the new organization will be to focus further on partnering with customers as part of Catalent’s New Product Introduction Excellence program.
An important factor in Catalent’s revenue and growth strategy, the program has expanded at a rate of over 70% over the past three years, from 59 new product launches globally in 2012, to 97 in 2013, and 175 in 2014.
Ms. Johnson will oversee a global function that includes more than 1,500 scientists, quality professionals and regulatory affairs experts. Catalent’s 300 R&D scientists work across 20 global development teams to develop up to 500 new products at any one time. Prior to assuming her new responsibilities, Ms. Johnson had served as Catalent’s Senior Vice President, Global Quality & Regulatory Affairs since 2009, having overseen the roll-out of Catalent’s Global Quality Management system to over 20 global sites. Ms. Johnson has thirty-plus years of experience in the pharmaceutical industry, including API and multiple dosages forms, from discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Ms. Johnson served as Vice President of Quality for GE Healthcare’s Medical Diagnostic Division, having previously worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.